Campese  

Steigerwalt  

  Resistant Hypertension: A Challenge for the Nephrologist Flash slide/audio
(ASN Renal Week Clinical Nephrology Conference Extract, November, 2008)
Campese: What are the main causes of resistant hypertension? How is nonadherence related to frequency of dosing? To what extent is weight loss important? Iatrogenic causes? Secondary hypertension? Sleep disorders? Steigerwalt: What is the prevalence of inappropriately high aldosterone in resistant hypertension? How can we safely use spironolactone and epleronone in such patients? What is the degree of blood pressure response to aldo blockers? What are the chances of developing hyperkalemia and how do we minimize this? Is amiloride useful? Do endothelin antagonists or long-acting nitrates have a role?
(more...)


Griffin  

Beddhu  

The Year in Nephrology: Hypertension and Metabolic Renal Syndrome

Karen Griffin, MD, and Srinivasan Beddhu, MD
(ASN Renal Week Clinical Nephrology Conference Extract, November, 2008.)
Griffin: What do recent hard outcomes trials show about the benefits of treating hypertension? Why was the AASK trial not very convincing in terms of BP control? What is the evidence comparing different classes of anti-hypertensive agents? What can we learn from susceptibility to renal injury vs. BP curve analysis? Why is renal autoregulation important? When is renal autoregulation impaired? What is the potential risk of calcium channel blockers in this regard? What is behind the synergy of ACE inhibitor type drugs and diuretics? How can we safely use calcium channel blocking drugs in CKD patients, or can we?
Beddhu: How do we define metabolic syndrome? What is its impact on progression of CKD. What is the impact of CKD on the cardiovascular effects of the metabolic syndrome? What are the therapeutic implications when confronted by a CKD patient with metabolic syndrome? How is adiponectin involved, both in nonuremic and CKD patients?
(more...)



Goldberg  

Schrier  

Gheorghiade

Restoring Balance: New Therapeutic Approaches to Acute Decompensated Heart Failure

Lee R. Goldberg, MD, Robert W. Schrier, MD, and Mihai Gheorghiade, MD
(ASN Renal Week Official Symposium, November, 2008.)
Goldberg: What is the epidemiology, natural history, and pathophysiology of acute heart failure? What do telemetry devices tell us about antecedent cardiac hemodynamics? What is the role of hypervolemia? Is it easily detectable? What do outcome trials tell us about the efficacy of various management options, including diuretics, vasodilators, inotropes, natriuretic peptides, and mechanical volume removal?
Schrier: What are the mechanisms of body fluid regulation? How do feedback mechanisms and vasoactive hormones contribute to disease? What are the mechanisms of hyponatremia? What is the role of AVP and V2-receptors? What happens when we give a V2 receptor antagonist? What happens when we give low-dose spironolactone? What are the positive vs. negative effects of loop diuretics?
Gheorghiade: What percent of ADHF patients present with congestion? How can this be managed? How is serum sodium related to outcome? What are our management strategies using diuretics, ultrafiltration, adenosine blocking agents, and vasopressin antagonists? What did the recent randomized trials show in terms of both soft and hard outcomes?
(more...)



Textor

Ischemic Nephropathy: Diagnosis and Management

Stephen C. Textor, MD
(ASN Board Review Course, August, 2008.)
Textor: What is the approach to ischemic nephropathy in 2008? What are the controversies? What is the prevalence? What is the impact of medical treatment with ACEI/ARB? What do the randomized trials show? Is revascularization still indicated? What are the clinical situations where revascularization can be defended? Are Doppler measures of resistivity helpful? What is BOLD MR?
(more...)



Textor

Dworkin

Controversies in Diagnosis and Treatment of Atherosclerotic Renovascular Disease

Stephen C. Textor, MD and Lance D. Dworkin, MD, FASN
(ASN Renal Week Clinical Nephrology Conference, November, 2007.)
Textor: What is significant renovascular disease? How do nephrologists vs. cardiologists vs. radiologists differ in their perspectives on this condition? What are the statistics regarding use of endovascular renal artery stenting? How does interventional treatment vary by geography? At what level of pressure drop does a stenosis affect renin levels? How do renal vascular lesions affect cardiovascular outcome? Renal outcome? Dworkin: How common is renal artery stenosis? How does it associate with other comorbidities? Survival? What are common justifications for its treatment? What are the main randomized trials of intervention vs. medical management and what did they show? What are their shortcomings? Why don't all patients respond to renin blockade? What is the impact of intervention on renal function? Does GFR correlate with extent of stenosis. Is flash pulmonary edema really related to renal artery stenosis? What about congestive heart failure? What is optimal medical therapy? What is the CORAL study and what is it designed to evaluate? How can we refer patients to this study? Note: The other 2 talks from this CNC are avaiable as audiofiles at this link.
(more...)



Calhoun

Rosenberg

Aldosterone: New Insights in Kidney Health and Disease

David A. Calhoun, MD and Mark E. Rosenberg, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2007.)
Calhoun: In normotensive individuals, how do aldo levels affect the risk of incident hypertension? What is the prevalence of aldosteronism in mild, moderate, and severe or resistant hypotension? What percent of this is due to adenoma? How effective is spironolactone as an anti-hypertensive drug? By how much does it lower blood pressure? Is spironolactone more effective in those patients with primary hyperaldosteronism? What is the risk of hyperkalemia with spironolactone, and how can this be mitigated? Rosenberg: What does the animal data show about use of aldosterone blockers in various animal models of CKD and/or renal injury? What do the clinical studies of spironolactone in CKD show? At what level of GFR do we need to start monitoring most closely for hyperkalemia? In 2008, can the use of aldosterone antagonists for CKD progression prevention be recommended?
(more...)
Updated: March 15, 2010 (Mar15)
Mar15 Valsartan and nateglitidine of no use in reducing CV death in prediabetics.
Mar15 Level of myeloperoxidase strongly associated with CAD mortality.
Mar15 ACCORD trial combination fibrate plus statin results (NEJM, pdf)
Mar15 ACCORD trial lower BP target results (NEJM, .pdf)
Mar15 ACCORD trial results released at ACC: BP lower than 120 or addition of fibrates have no benefit in diabetics.
Mar12 Plavix gets new FDA warning regarding reduced efficacy in 3% slow activators.
Mar12 Spikes in blood pressure predict stroke risk better than high average readings.
Mar11 NEJM: Thyroid hormone analogue lowers LDL cholesterol in statin-treated patients.
Mar04 NEJM: Glycated hemoglobin linked to CV death risk in nondiabetic adults.
Mar02 3 different diets equivalent in terms of improving carotid artery atherosclerosis.
Mar01 Leukocyte biology suggests that simvastatin may increase infection risk.
Feb23 AHA/ACC issue Science Advisory re heart risk and thiazolidinedione drugs.
Feb23 New cardiac CT scanners with 320 detector rows expose patients to 90% less radiation.
Feb22 Mutations in gene encoding K channel KCNN3 associated with atrial fibrillation.
Feb12 Tetrahydrobiopterin (BH4) a drug already used in humans, prevents diastolic heart failure in mice.
Industry Advances Emphasis
archive
What is the Role of Aldosterone Blockade and Other Newer Antihypertensive Therapies in the Management of Resistant Hypertension? (P. Steigerwalt,) ASN Renal Week 2008
Clinical: How Do We Treat Them? (B. Chonchol) ASN Renal Week 2008
Case Summary - Questions & Answers (Himmelfarb) ASN Renal Week 2008
Basic: The Local RAAS in the Macrophage: Implications for Vascular Disease (Daugherty) ASN Renal Week 2008
Is Hypertension Essential for Survival in the Elderly? (H. Laragh) ASN Renal Week 2008
Debate: Does Lowering Cholesterol Prevent Cardiovascular Events in Patients with Advanced Kidney Disease?  Observational Study versus Randomized Controlled Trial Data (J. Landray) ASN Renal Week 2008
Clinical: How to Calm the Vessel in CKD (Himmelfarb) ASN Renal Week 2008
Basic: Which Lipids Matter? (D. Vaziri) ASN Renal Week 2008
Hypertension (A. Griffin) ASN Renal Week 2008
Role of Oxidative Stress and Endothelial Dysfunction in the Pathogenesis of Hypertension (Himmelfarb) ASN Renal Week 2008
Coronary Artery Disease (J. Vergne-Marini) ASN Renal Week 2008
What's New in Etiology/Biology? (A. Eisenberg) ASN Renal Week 2008
Contributing Factors to Resistant Hypertension: Salt, Substance Use, Sleep Disorders, and Non-Adherence (M. Campese) ASN Renal Week 2008
Restoring Balance: New Therapeutic Approaches to Acute Decompensated Heart Failure (Goldberg, Schrier, Gheorghiade) ASN Renal Week 2008
Intradialytic Hypotension:  Prevention and Clinical Management (Hossli) ADC 2008
Lipid-Lowering Treatment for All Patients with End-Stage Renal Disease? (Gardner) ADC 2008
How Does Volume Status Affect Brain Natriuretic Peptide and Troponin Levels as Markers of Cardiovascular Status in PD Patients? (Aggarwal) ADC 2008
Ischemic Nephropathy: Diagnosis and Management (Textor) ASN Board Review 2008
Does Reverse Epidemiology Imply That Hyperlipidemia and Hypertension Should Not Be Treated? (Kalantar-Zadeh) ADC 2008
Importance of Optimal Blood Pressure Control (Kathuria) ADC 2008
Cardiovascular Disease in ESRD - Are Genes to Blame? (Balakrishnan) ADC 2008
Pulmonary Hypertension in HD Patients (Rai) ADC 2008
Increasing Survival in Advanced CKD and ESRD: The Role of Dialysis Providers in Assessing and Managing Cardiovascular Disease (Schiller) ADC 2008
Non-osmotic sodium interaction with hypertension and tissue hydration (Titze) RRI 2008
Angiotensin II, interstitial inflammation and the pathogenesis of salt sensitive hypertension (Franco) RRI 2008
Heart rate variability and sympathetic function in CKD—implications for management (T. Chan) RRI 2008
Sudden death in dialysis patients (Ritz) RRI 2008
What is Significant Renovascular Disease: A Cardiologist's, Nephrologist's, or Radiologist's Decision? (C. Textor) ASN Renal Week 2007
Challenges in Volume Management. Optimizing Care in Patients with Heart Failure and Renal Dysfunction (Burnett, Fowler, Gheorghiade) ASN Renal Week 2007
Intrarenal vs. Systemic AT1 Receptor: Which Mediates Injury? (D. Crowley) ASN Renal Week 2007
Controversies in Diagnosis and Treatment of Atherosclerotic Renovascular Disease (Textor, Dworkin) ASN Renal Week 2007
Primary Hyperaldosteronism: Not Such a Rare Cause of Hypertension? (A. Calhoun) ASN Renal Week 2007
The Other CVD Risk Factor: How to Achieve Goals of Treatment (B. Hampl) ASN Renal Week 2007
Oxidative Stress, CRP-leptin, and Inflammation in CKD Patients with CVD (S. Balakrishnan) ASN Renal Week 2007
Sudden Death Prevention (J. Bleyer) ASN Renal Week 2007
The Vascular "Check-Up": Endothelial Action and Clinical Relevance (L. Schiffrin) ASN Renal Week 2007
Mending Heartbreak in CKD: Succeeding in Secondary Prevention (J. Sarnak) ASN Renal Week 2007
Looking Under the Hood: What GRK4 Mutations and Other Genetic Causes of Hypertension Teach Us (A. Jose) ASN Renal Week 2007
Presidential Address (L. Henrich) ASN Renal Week 2007
Too Much of a Good Thing in the Wrong Place (J.L. Bakker) ASN Renal Week 2007
Case 2: The 65 Year Old Diabetic with a Prior Stroke (C. Brosius) ASN Renal Week 2007
Endothelial Function/Dysfunction: What Does It Mean and Why Does It Matter? (S. Goligorsky) ASN Renal Week 2007
Cardiovascular Risk factors and Mortality in Pediatric ESRD (Mitsnefes) ASN Renal Week 2007
Peripheral Vascular Disease: Assessments and Approaches to Care (B. Froehlich) ASN Renal Week 2007
Vasopressin Antagonists in the Treatment of Congestive Heart Failure (Gross) ASN Renal Week 2007
Renovascular Ischemia: A Common Cause of Chronic Kidney Disease? (L. Linas) ASN Renal Week 2007
Not All Lipids Are Created Equal: Diabetes and CKD (Levi) ASN Renal Week 2007
Vasopressin Antagonists in the Treatment of Syndrome of Inappropriate Antidiuretic Hormone Secretion Robert W. Schrier Endowed Lectureship (G. Verbalis) ASN Renal Week 2007
Vasopressin Antagonists: Physiology and Mechanisms of Action (W. Schrier) ASN Renal Week 2007
Veinus de Milo: How Vessels Calcify (M. Moe) ASN Renal Week 2007
Risk of Stroke in Chronic Kidney Disease (E. Weiner) ASN Renal Week 2007
Burden of Cardiovascular Disease Risk Factors in Chronic Kidney Disease (G. Shlipak) ASN Renal Week 2007
The (Pro)Renin Receptor (Nguyen) ASN Renal Week 2007
Treatment of Atherosclerotic CVD in Advanced CKD (Tonelli) ASN Renal Week 2007
Clues in Pregnant Hypertensives: Suspects? Venue? Weapons? (August) ASN Renal Week 2007
Treatment of Renal Artery Stenosis: Medical versus Vascular Intervention (D. Dworkin) ASN Renal Week 2007
Methods and Accuracy of Diagnosis of Significant Renal Artery Stenosis: Are We Getting Better? (F. King) ASN Renal Week 2007
Public Health Implications of CKD as a CHD Risk Equivalent (Muntner) ASN Renal Week 2007
Beyond Levi Strauss: Genetic Components and Other Clues (G. Warnock) ASN Renal Week 2007
Why Does the Glomerulus Leak? (Yee) ASN Renal Week 2007
Mechanisms of Aldosterone-Mediated Fibrosis (Gamba) ASN Renal Week 2007
Vasopressin Antagonists in the Clinical Arena: Better, More Expensive, or Both? A Skeptic's View (F. Palmer) ASN Renal Week 2007
Fetuin and Adiponectin Predict CVD in CKD (Mehrotra) ASN Renal Week 2007
Case 1: The 51 Year Old AA Woman with a Creatinine of 2.1 and Hyperlipidemia (R. Townsend) ASN Renal Week 2007
Treatment of Hypertension (T. Turner) ASN Renal Week 2007
Aldosterone: Issues in Regulation of Blood Pressure and Sodium Transport (H. Ellison) ASN Renal Week 2007
ACE2 and Ang1-7 Barry M. Brenner Endowed Lectureship (M. Ferrario) ASN Renal Week 2007
Slip-Sliding Along: Lowering Lipids (M. Campese) ASN Renal Week 2007
Progression of Renal Disease and Aldosterone Antagonists in Chronic Kidney Disease (E. Rosenberg) ASN Renal Week 2007
Aldosterone: New Insights in Kidney Health and Disease (Calhoun, Rosenberg) ASN Renal Week 2007
Cardiovascular Disease in End Stage Renal Disease Patients (Henrich) ASN Board Review 2007
Hypertension, LVH and Natriuretic Hormones in HD Patients (Reams) ADC 2007
High Blood Pressure is Detrimental for HD Patients (Charra) ADC 2007
Lipid Management in ESRD: Does it Make a Difference? (Kathuria) ADC 2007
High Blood Pressure is Not Harmful for HD Patients (Kalantar-Zadeh) ADC 2007
Fighting Sudden Death in Dialysis Patients: A Cardiologist’s Perspective (A. Herzog) RRI 2007
Pathogenesis and Management of Cardiovascular Disease (CVD) in Chronic Kidney Disease ASN Renal Week 2006
Secondary Hypertension, including Chronic Kidney Disease ASN Board Review 2006
Blood Pressure on Dialysis (Kalantar-Zadeh, Reams, Misra, Sherman, Charra) ADC 2006 (audiofiles)
Update on Vascular Calcification in Chronic Kidney Disease (CKD) Patients (Isaac Teitelbaum, MD; Robert Toto, MD; Dennis Andress, MD; Gerard M. London, MD) ADC 2006 (audio only)
Webcasts from the ISH 2006 meeting in Fukuoka, Japan, October, 2006 (ISH 2006) ADC 2006 (audiofiles)
Uric acid as a Uremic Toxin (Ikizler, Nakagawa) RRI 2006, Part 2 (handouts)
Sodium as a Uremic Toxin (Ritz) RRI 2006, Part 2 (handouts)
Kidneys, Hearts, Hormones, Immunomodulators and More: Complex Systems Requiring Integrated Understandings (Adeera Levin) RRI 2006, Part 2 (handouts)
Cardiovascular Disease Causes and Consequences of Sympathetic Hyperactivity in CKD (Kotanko) RRI 2006, Part 3 (handouts)
Dry Weight Assessment and Rebound (Kuhlmann, Greenwood) RRI 2006, Part 3 (handouts)

Gitelman Syndrome (Roser M et al) Hypertension (Jun 2009)
Hypertension, Salt and Bread (Akpolat et al) Am J Kidney Dis (Jun 2009)
Atrial Fibrillation and Heart Failure: Treatment Considerations for a Dual Epidemic (Anter et al) Circulation (May 2009)
Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies (Law MR et al) BMJ (May 2009)
How little aldosterone is able to raise blood pressure? (Ritz) Clin J Am Soc Nephrol (Apr 2009)
The genetic basis of kidney disease risk in African Americans: MYH9 as a new candidate gene Am J Kidney Dis (Apr 2009)
Acute and chronic management of atrial fibrillation in patients with late-stage CKD Am J Kidney Dis (Apr 2009)
A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial Hypertens (Apr 2009)
Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure (Siedlecki) Kidney Int (Apr 2009)
Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force Recommendation Statement Ann Intern Med (Mar 2009)
The ubiquitous nature and elusive role of phosphorus and vascular calcification Am J Kidney Dis (Mar 2009)
AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: Part IV: The ST segment, T and U Waves, and the QT interval Circulation (Mar 2009)
Dietary salt intake, salt sensitivity, and cardiovascular health Hypertens (Mar 2009)
AHA/ACCF/HRS recommendations for the standardization and interpretation of the ECG: part V: changes associated with cardiac chamber hypertrophy Circulation (Mar 2009)
AHA Scientific Statements: Implementing American Heart Association Pediatric and Adult Nutrition Guidelines Circulation (Mar 2009)
A patient's guide to taking coumadin/warfarin Circulation (Mar 2009 )
Is angiotensin-converting enzyme inhibitor and angiotensin receptor blocker combination therapy better than monotherapy and safe in patients with CKD? Am J Kidney Dis (Feb 2009)
Phosphate - the silent stealthy cardiorenal culprit in all stages of chronic kidney disease Blood Purif (Feb 2009)
Spironolactone suppresses inflammation and prevents L-NAME- induced renal injury in rats Kidney Int (Jan 2009)
Variability of ferritin measurements in chronic kidney disease; implications for iron management Kidney Int (Jan 2009)
The new role of calcimimetics as vasculotropic agents Kidney Int (Jan 2009)
Atherosclerotic peripheral vascular disease symposium II: vascular magnetic resonance and computed tomographic imaging Circulation (Jan 2009)
Atherosclerotic peripheral vascular disease symposium II: intervention for renal artery disease Circulation (Jan 2009)
Atherosclerotic peripheral vascular disease symposium II: stroke intervention: state of the art Circulation (Jan 2009)
Pregnancy and the kidney J Am Soc Nephrol (Jan)
Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children Study Hypertens (Oct 2008)
Oral estrogen therapy in postmenopausal women is associated with loss of kidney function Kidney Int - Aug - 08
Cholesteryl Ester Transfer Protein Inhibition for Coronary Heart Disease Prevention: Real Hope or Despair? (Frishman WH and Barkowski RS) Am J Med (Aug 2008)
Exercise in Dialysis Patients: A Review (Johansen K) Hemodial Int - Jul - 08
Population-based prevention of obesity: the need for comprehensive promotion of healthful eating, physical activity, and energy balance: A Scientific Statement From American Heart Association (Kumanyika SK et al) Circulation Jul 08
Dyslipidemia in CKD: An approach to pathogenesis and treatment. (Tsimihodimos) (Am J Nephrol Jul 2008)
Resistant hypertension: diagnosis, evaluation, and treatment Circulation (Jul 2008)
Treating elderly people with diabetes and stages 3 and 4 chronic kidney disease CJASN (Jul 2008)
Abrupt shift of the pattern of diurnal variation in stroke onset with daylight saving time transitions (Foerch C et al) Circulation - Jul 08
Dietary sodium and cardiovascular and renal disease risk factors: dark horse or phantom entry? (McCarron DA) NDT Jul 08
Ambulatory blood pressure monitoring in children and adolescents: recommendations for standard assessment: A Scientific Statement From the AHA. Hypertens (Sep 2008)
Noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the American Heart Association and related societies Circulation (Sep 2008)
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus...optimizing platelet inhibition with prasugrel-thrombolysis Circulation (Oct 2008)
Nonphosphate-binding effects of sevelamer -- are they of clinical relevance? Semin Dial (Oct 2008)
C-reactive protein and parental history improve global cardiovascular risk prediction: The Reynolds Risk Score for men Circulation (Nov 2008)
Salt, salt substitutes, and seasoning alternatives J Ren Nutr (Nov 2008)
Epithelial sodium channel: Mendelian versus essential hypertension Hypertens (Oct 2008)
The impact of systemic calcified atherosclerosis in patients with chronic kidney disease Adv Chronic Kidney Dis (Oct 2008)
Dietary sodium and cardiovascular and renal disease risk factors: dark horse or phantom entry? Nephrol Dial Transplant (Jul 2008)
Abrupt shift of the pattern of diurnal variation in stroke onset with daylight saving time transitions Circulation (Jul 2008)
Noninvasive Coronary Artery Imaging: Magnetic Resonance Angiography and Multidetector Computed Tomography Angiography: (AHA Scientific Statement) Circulation (July 2008)
Lewis K. Dahl Memorial Lecture: The renin-angiotensin system and aging Hypertens (Jul 2008)
Sympathetic overactivity - the Cinderella of cardiovascular risk factors in dialysis patients Semin Dial (Aug 2008)
Dual inhibition with losartan and aliskiren: a promising therapeutic option for type 2 diabetic nephropathy? Nature Clin Pract Nephrol (Dec)
Rosuvastatin to prevent vascular events in men and womenwith elevated C-reactive protein N Engl J Med (Nov 2008)
Changes in serum potassium mediate thiazide-induced diabetes Hypertens (Dec 2008)
Hypertension-associated kidney disease: perhaps no more J Am Soc Nephrol (Nov 2008)
Fifty years of beta-adrenergic blockade: a golden era in clinical medicine and molecular pharmacology Am J Med (Nov 2008)
Sleep Apnea and Cardiovascular Disease: An American Heart Association/American College of Cardiology Foundation Scientific Statement. Circulation (Sep 2008)
Left ventricular hypertrophy and cardiovascular mortality by race and ethnicity Am J Med (Oct 2008)
Passive smoking and risk of peripheral arterial disease and ischemic stroke in chinese women who never smoked Circulation (Oct 2008)
Lipid abnormalities and cardiovascular risk in renal disease J Am Soc Nephrol (Jun 2008)
Should patients with venous thromboembolism be screened for thrombophilia? Am J Med (Jun 2008)
Pleiotropic effects of telmisartan: still more to come? J Hypertens (May 2008)
Prevention of heart failure: a scientific statement from the American Heart Association Councils Circulation (May 2008)
Efficacy and safety of fondaparinux and enoxaparin for acute coronary syndromes in CKD Am J Kidney Dis (May 2008)
ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities Circulation (May 2008)
Targeting proteinuria as a valid surrogate for individualized kidney protective therapy Am J Kidney Dis (May 2008)
Lipoprotein management in patients with cardiometabolic risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation Diabet Care (Apr 2008)
Revisiting the dialysate sodium prescription as a tool for better blood pressure and interdialytic weight gain management in hemodialysis patients Clin J Am Soc Nephrol (Mar 2008)
Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension Kidney Int (Mar 2008)
Systolic hypertension in the elderly: addressing an unmet need Am J Med (Mar 2008)
Supratherapeutic doses of angiotensin receptor blockers to decrease proteinuria in patients with chronic kidney disease Am J Nephrol (Mar 2008)
Hyperglycemia and acute coronary syndrome: A Scientific Statement From the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism Circulation (Mar 2008)
Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease Am J Nephrol (Mar 2008)
Effect of the Italian smoking ban on population rates of acute coronary events Circulation (Mar 2008)
Mechanisms of vascular calcification in chronic kidney disease J Am Soc Nephrol (Feb 2008)
Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease Nephrol Dial Transplant (Feb 2008)
Association between obesity and kidney disease: A systematic review and meta-analysis Kidney Int (Jan 2008)
Beta-blockade in chronic dialysis patients Semin Dial (Feb 2008)
2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention Circulation (Jan 2008)
Poor correlation between coronary artery calcification and obstructive coronary artery disease in an end-stage renal disease patient Hemodial Int (Jan 2008)
Atheroembolic renal disease: A silent masquerader Kidney Int (Jan 2008)
2007 Chronic angina focused update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina: A Report of the ACC/AHA Task Force (Fraker Jr et al) Diabet Care (Dec 2007)
Long term pharmacotherapy for obesity and overweight: updated meta-analysis (Rucker et al) Brit Med J (Dec 2007)
Evidence for the Reaffirmation of the U.S. Preventive Services Task Force Recommendation on Screening for High Blood Pressure (Wolff et al) Ann Intern Med (Dec 2007
Safety of magnetic resonance imaging in patients with cardiovascular devices: An American Heart Association Scientific Statement (Levin et al) Circulation (Dec 2007)
Thiazide-induced subtle renal injury not observed in states of equivalent hypokalemia (Reungjui et al) Kidney Int (Dec 2007)
Hypertension in pregnancy: an emerging risk factor for cardiovascular disease (Garovic et al) Nature Clin Pract Nephrol (Nov 2007)
Inherited arrhythmias: A National Heart, Lung, and Blood Institute and Office of Rare Diseases Workshop Consensus Report (Lenhart et al) Circulation (Nov 2007)
The pivotal role of sodium balance in control of blood pressure in dialysis patients (Tomson et al) Hemodial Int (Nov 2007)
Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysis (Chong et al) Brit Med J (Oct 2007)
Peripheral artery disease and hypertension: the relation between ankle-brachial index and mortality (Karthikeyan et al) J Hum Hypertens (Oct 2007)
The 2007 revised ESC/ESH Guidelines in the management of hypertension: clarifying individual patient care (MacFayden) J Hum Hypertens (Oct 2007)
Resistant hypertension and aldosterone excess: new insights from ambulatory blood pressure monitoring (Grassi et al) J Hypertens (Oct 2007)
Obesity paradox in patients with hypertension and coronary artery disease (Lavie et al) Am J Med (Oct 2007)
ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery (Fleisher et al) Circulation (Oct 2007)
Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non-ST-segment-elevation acute coronary syndrome (Scirica et al) Circulation (Oct 2007)
Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trial (Bakris et al) Kidney Int (Oct 2007)
Prevention of Infective Endocarditis: Guidelines From the American Heart Association and other organizations (Wilson et al) Circulation (Oct 2007)
Cardiac troponin assays: a view from the clinical chemistry laboratory (Melanson et al) Circulation (Oct 2007)
Association of antihypertensive therapy and diastolic hypotension in chronic kidney disease (Peralta et al) Hypertens (Sep 2007)
Is there an unrecognized epidemic of primary aldosteronism? (debate) (Calhoun & Kaplan) Hypertens (Sep 2007)
Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates (Elliot) Am J Kidney Dis (Sep 2007)
High salt intake: a cause of blood pressure-independent left ventricular hypertrophy? (Burnier et al) Nephrol Dial Transplat (Sep 2007)
Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review (Eurich et al) Brit Med J (Sep 2007)
Physical activity and public health in older adults Circulation (Aug 2007)
Independent impact of gout on mortality and risk for coronary heart disease (Choic et al) Circulation (Aug 2007)
ACC/AHA 2007 Guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction Circulation (Aug 2007)
What adult nephrologists should know about childhood blood pressure (Hadstein et al) Nephrol Dial Transplant (Aug 2007)
Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum (Glassock) J Am Soc Nephrol (Aug 2007)
The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio (Hood et al) Adv Chronic Kidney Dis (Jul 2007)
The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) Double-Blind Crossover Trial in Patients With Low-Renin Hypertension and Elevated Aldosterone-Renin Ratio (Hood SJ et al) Circulation (Jul 07)
Influence of acute and chronic mineralocorticoid excess on endothelial function in healthy men (Nietlispach et al) Hypertens (Jul 2007)
Are we overestimating left ventricular abnormalities in end- stage renal disease? (Mark et al) Nephrol Dial Transplan (Jul 2007)
A different approach to resistant hypertension (Hirsch S) Cleveland Clinic J Med (Jun 07)
Intensive versus moderate blood-pressure control in normotensive patients with type 2 diabetes (Briggs J) NCPN Jun 07
Pulse wave velocity is inversely related to vertebral bone density in hemodialysis patients (Raggi et al) Hypertens (Jun 2007)
A young woman with neurofibromatosis and severe hypertension (Gold et al) Am J Med (Jun 2007)
Pathophysiology of the clinical manifestations of preeclampsia (Hladunevich et al) Clin J Am Soc Nephrol (May 2007)
Treatment of hypertension in the prevention and management of ischemic heart disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure et al (O'Gara et al) Circulation (May 2007)
Lipoprotein metabolism and lipid management in chronic kidney disease JASN 04-07
Controveries in renal artery stenosis: A review by the American Society of Nephrology Advisory Group on Hypertension (Levin et al) Am J Nephrol 04-07
Controveries in renal artery stenosis: A review by the American Society of Nephrology Advisory Group on Hypertension (Levin A et al) Am J Nephrol (04-2007)
ACCF/AHA 2007 Clinical Expert Consensus Document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain. Circulation (02-07)
Aldosterone and Cardiovascular Disease. Smoke and Fire (Calhoun). Circulation 12-06
Effectiveness of Management Strategies for Renal Artery Stenosis: A Systematic Review (Balk et al) Annals Intern Med 12-06
Physical Activity Intervention Studies: What We Know and What We Need to Know (AHA) Circulation 12-06
Angiotensin-converting enzyme-2 (ACE-2) - a new player in the genesis of glomerular injury? (Comment by Ritz on paper by Oudit et al) JASN 10-06
Obesity: Growing Impact on CKD (McGill, Furth, Kaskel) Adv Chronic Kidney Dis 10-06
Management of dyslipidemias in patients with diabetes and chronic kidney disease (Molitch). CJASN 09-06
KDOQI
K-DOQI Lipid Guidelines
Other Guidelines
JNC 7
HTN in Pregnancy
ADA Clinical Practice Recs
Canadian Lifestyle Guidelines
Guidelines.gov
Patient info
Salt Reduction Guide
DASH Diet Facts
American Heart Assoc
National Stroke Assoc
NHLBI - Patient guide
Topic Pages
Renovascular HTN (Nuc Med)
Ambulatory BP Monitoring
Arm Cuff Measurement
ACEI, AII Blockers
Beta Blockers
Ca Antagonists
Beta Blockers
Heart in HTN
Kidney in HTN
Genetics
Hormonal Physiology
Inflammatory Syndrome
Salt Sensitivity
Outcomes
Elderly
Endocrine
Syndrome X, Diabetes
Lipid Disorders
Smoking
Renovascular
HTN in Women
Research
Clinical Trials (NIH)
Patient Info
Salt, the Forgotten Killer
Lowering your BP with DASH
Tools, Calculators
CV Risk Calculator

Dr. Carmine Zoccali, M.D.
Postgraduate Professor of Nephrology, Director, Center for Clinical Physiology, Renal Diseases and Hypertension of the Italian Research Council, Reggio Calabria, Italy (European Editor)